Compare · CI vs SERA
CI vs SERA
Side-by-side comparison of The Cigna Group (CI) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.96B, about 986.0x SERA ($80.1M).
- CI has been more active in the news (5 items in the past 4 weeks vs 1 for SERA).
- CI has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- The Cigna Group
- Sera Prognostics Inc.
- Price
- -
- -
- Market cap
- $78.96B
- $80.1M
- 1M return
- +9.55%
- -
- 1Y return
- +0.96%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 8
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)
Latest SERA
- SEC Form 4 filed by Sera Prognostics Inc.
- Chief Executive Officer Lindgardt Zhenya sold $14,044 worth of shares (7,022 units at $2.00), decreasing direct ownership by 0.83% to 837,848 units (SEC Form 4) to satisfy withholding tax
- General Counsel Jackson Benjamin sold $4,380 worth of shares (2,190 units at $2.00), decreasing direct ownership by 1% to 159,566 units (SEC Form 4) to satisfy withholding tax
- Chief Commercial Officer Anderson Dyaarl Lee Jr. sold $3,600 worth of shares (1,800 units at $2.00), decreasing direct ownership by 2% to 76,198 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Inglis Tiffany Eul Davis sold $972 worth of shares (486 units at $2.00), decreasing direct ownership by 0.53% to 91,589 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Lindgardt Zhenya sold $40,278 worth of shares (20,139 units at $2.00), decreasing direct ownership by 2% to 844,870 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by Chief Financial Officer Aerts Austin
- SEC Form 3 filed by new insider Gleason Scott
- Chief Financial Officer Gleason Scott was granted 117,924 shares (SEC Form 4)
- 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.